BRPI0606463A2 - derivados triazol substituìdos com antagonistas de oxitocina - Google Patents

derivados triazol substituìdos com antagonistas de oxitocina

Info

Publication number
BRPI0606463A2
BRPI0606463A2 BRPI0606463-9A BRPI0606463A BRPI0606463A2 BR PI0606463 A2 BRPI0606463 A2 BR PI0606463A2 BR PI0606463 A BRPI0606463 A BR PI0606463A BR PI0606463 A2 BRPI0606463 A2 BR PI0606463A2
Authority
BR
Brazil
Prior art keywords
triazole derivatives
substituted triazole
oxytocin antagonist
substituted
oxytocin
Prior art date
Application number
BRPI0606463-9A
Other languages
English (en)
Inventor
Alan Daniel Brown
David Ellis
Andrew Antony Calabrese
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BRPI0606463A2 publication Critical patent/BRPI0606463A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS TRIAZOL SUBSTITUìDOS COMO ANTAGONISTAS DE OXITOCINA. A presente invenção refere-se a triazóis substituidos de fórmula (1) , a usos dos mesmos, processos para preparação dos mesmos, e a composições contendo esses compostos. Esses inibidores têm utilidade numa série de aplicações terapêuticas, incluindo disfunção sexual.
BRPI0606463-9A 2005-01-20 2006-01-11 derivados triazol substituìdos com antagonistas de oxitocina BRPI0606463A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals
PCT/IB2006/000118 WO2006077496A1 (en) 2005-01-20 2006-01-11 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
BRPI0606463A2 true BRPI0606463A2 (pt) 2009-06-30

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606463-9A BRPI0606463A2 (pt) 2005-01-20 2006-01-11 derivados triazol substituìdos com antagonistas de oxitocina

Country Status (31)

Country Link
US (5) US7557131B2 (pt)
EP (1) EP1841758B1 (pt)
JP (1) JP4124805B1 (pt)
KR (1) KR100936854B1 (pt)
CN (1) CN101107243B (pt)
AP (1) AP2007004047A0 (pt)
AR (1) AR055303A1 (pt)
AT (1) ATE449091T1 (pt)
AU (1) AU2006207300B2 (pt)
BR (1) BRPI0606463A2 (pt)
CA (1) CA2595569C (pt)
CR (1) CR9219A (pt)
DE (1) DE602006010508D1 (pt)
DK (1) DK1841758T3 (pt)
DO (1) DOP2006000014A (pt)
EA (1) EA200701328A1 (pt)
ES (1) ES2334517T3 (pt)
GB (1) GB0501190D0 (pt)
GT (1) GT200600024A (pt)
IL (1) IL184148A (pt)
MA (1) MA29160B1 (pt)
MX (1) MX2007008757A (pt)
NL (1) NL1030961C2 (pt)
NO (1) NO338420B1 (pt)
PA (1) PA8660401A1 (pt)
PE (1) PE20060875A1 (pt)
TN (1) TNSN07275A1 (pt)
TW (1) TW200637847A (pt)
UY (1) UY29339A1 (pt)
WO (1) WO2006077496A1 (pt)
ZA (1) ZA200705718B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
EP1902051A1 (en) * 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
WO2007143823A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7754745B2 (en) * 2006-06-13 2010-07-13 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2685029A1 (en) * 2007-04-26 2008-11-06 Avalon Pharmaceuticals Multi-ring compounds and uses thereof
CA2712701A1 (en) * 2008-01-31 2009-08-06 Henning Steinhagen Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
CN101981006B (zh) * 2008-01-31 2013-08-28 赛诺菲-安万特 环状吲哚-3-甲酰胺、其制备和其作为药物的用途
SG11201500234YA (en) * 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10875829B1 (en) 2016-11-18 2020-12-29 Integrative Research Laboratories Sweden Ab Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
AU2017379024B2 (en) * 2016-12-21 2021-03-04 Jiangsu Hengrui Medicine Co., Ltd. Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
TW201823231A (zh) * 2016-12-28 2018-07-01 大陸商江蘇恆瑞醫藥股份有限公司 氮雜雙環基取代的三唑類衍生物、其製備方法及其在醫藥上的應用
WO2019242642A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
WO2019242646A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 催产素受体抑制剂的晶型及其制备方法
WO2020001460A1 (zh) * 2018-06-27 2020-01-02 江苏恒瑞医药股份有限公司 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
JP2025508714A (ja) * 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
WO1997036897A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000509371A (ja) 1996-04-03 2000-07-25 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
EP0904076A1 (en) 1996-04-03 1999-03-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9813699A (pt) 1997-12-16 2000-10-10 Pfizer Prod Inc Combinação eficaz para o tratamento da impotência
BR0012697A (pt) 1999-07-23 2002-04-09 Shionogi & Co Inibidores da diferenciação de th2
TR200201023T2 (tr) 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
JP4883862B2 (ja) 1999-11-15 2012-02-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼ阻害剤としてのトリアゾール類
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
HUP0302415A2 (hu) * 2000-05-19 2003-11-28 Merck Patent Gmbh Triazolszármazékokat tartalmazó gyógyszerkészítmények és új triazolszármazékok
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
MXPA04003170A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion.
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
JP2007505888A (ja) * 2003-09-22 2007-03-15 ファイザー インコーポレイテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
US20150322042A1 (en) 2015-11-12
NO20074177L (no) 2007-10-16
DK1841758T3 (da) 2010-01-18
MX2007008757A (es) 2008-03-10
TW200637847A (en) 2006-11-01
DOP2006000014A (es) 2006-07-31
KR20070091023A (ko) 2007-09-06
AU2006207300B2 (en) 2011-03-03
US9023872B2 (en) 2015-05-05
ZA200705718B (en) 2008-08-27
US8207198B2 (en) 2012-06-26
JP4124805B1 (ja) 2008-07-23
US7557131B2 (en) 2009-07-07
IL184148A (en) 2013-06-27
GT200600024A (es) 2006-08-23
US20170114040A1 (en) 2017-04-27
CA2595569C (en) 2010-07-20
US20060160786A1 (en) 2006-07-20
DE602006010508D1 (de) 2009-12-31
KR100936854B1 (ko) 2010-01-14
CR9219A (es) 2007-07-24
NL1030961C2 (nl) 2007-01-12
TNSN07275A1 (fr) 2008-12-31
UY29339A1 (es) 2006-08-31
JP2008528476A (ja) 2008-07-31
PA8660401A1 (es) 2006-09-08
US20090253674A1 (en) 2009-10-08
CA2595569A1 (en) 2006-07-27
NO338420B1 (no) 2016-08-15
WO2006077496A1 (en) 2006-07-27
IL184148A0 (en) 2007-10-31
AP2007004047A0 (en) 2007-06-30
EP1841758A1 (en) 2007-10-10
US20130137671A1 (en) 2013-05-30
PE20060875A1 (es) 2006-09-04
EA200701328A1 (ru) 2007-12-28
EP1841758B1 (en) 2009-11-18
ES2334517T3 (es) 2010-03-11
AR055303A1 (es) 2007-08-15
AU2006207300A1 (en) 2006-07-27
ATE449091T1 (de) 2009-12-15
NL1030961A1 (nl) 2006-07-21
CN101107243A (zh) 2008-01-16
MA29160B1 (fr) 2008-01-02
CN101107243B (zh) 2010-11-24
HK1113927A1 (en) 2008-10-17
US10150752B2 (en) 2018-12-11
US9394278B2 (en) 2016-07-19
GB0501190D0 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
MX2013004491A (es) Boronatos como inhibidores de arginasa.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
NZ588830A (en) Inhibitors of protein kinases
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
DK1678166T3 (da) Proteinkinaseinhibitorer
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
UY30282A1 (es) Compuestos quimicos
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
PH12014502241A1 (en) Pharmaceutical formulations comprising ccr3 antagonists
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX2007013624A (es) Inhibidores de proteina cinasa.
BRPI0414663A (pt) derivados triazol substituìdos como antagonistas de oxitocina
TW200626593A (en) Novel compounds
MX2009007429A (es) Compuestos de piridina y su uso como antagonistas de p2y12.
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.